Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-7172 tablets and others received drug clinical trial approval notices.

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that recently, the company and its subsidiaries received the "Drug Clinical Trial Approval Notices" approved and issued by the National Medical Products Administration for HRS-7172 tablets, Adebrelimab Injection, SHR-4610 Injection, SHR-8068 Injection, SHR-9839 (sc) for injection, SHR-1826 for injection, Bevacizumab Injection, HRS-4642 Injection, HRS-6093 tablets, and HRS-7058 capsules, and will soon initiate clinical trials. According to the "Drug Administration Law of the People's Republic of China" and relevant regulations, upon review, the clinical trial applications for HRS-7172 tablets, Adebrelimab Injection, SHR-4610 Injection, SHR-8068 Injection, SHR-9839 (sc) for injection, SHR-1826 for injection, Bevacizumab Injection, HRS-4642 Injection, HRS-6093 tablets, and HRS-7058 capsules accepted on May 18, 2026 comply with the relevant requirements for drug registration, and clinical trials are approved to be conducted. Specifically: an open-label, multicenter Phase IB/II clinical study of HRS-7172 in combination with anti-tumor therapy for the safety, tolerability, and efficacy in participants with solid tumors.